Oncternal Therapeutics Inc expected to post a loss of $2.88 a share - Earnings Preview

Oncternal Therapeutics

30/04/2024 12:21

* Oncternal Therapeutics Inc  ONCT.OQ   ONCT.O  is expected
to show a fall in quarterly revenue when it reports  results on
May 2 (estimated) for the period ending March 31 2024
    * The San Diego California-based  company is expected to
report a
13.0% decrease in revenue to $176.67 thousand from $203 thousand
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Oncternal Therapeutics
Inc is
for a loss of $2.88 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $28.00​, above​ its last closing price
of $8.48. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -3.38       -3.07      -3.11     Missed  -1.4
 Sep. 30 2023  -3.02       -2.90      -3.40     Missed  -17.2
 Jun. 30 2023  -2.88       -3.20      -3.00     Beat    6.3​
 Mar. 31 2023  -3.94       -4.07      -4.00     Beat    1.6
 ​​Dec.        -4.00       -4.17      -4.00     Beat    4
 31 2022                                                
 Sep. 30 2022  -4.78       -4.73      -4.20     Beat    11.3​
 Jun. 30 2022  -4.33       -4.57      -4.60     Missed  -0.7
 Mar. 31 2022  -4.05       -4.05      -4.00     Beat    1.2
 This summary was machine generated April 30 at 11:21 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)